{
  "objCls" : "Guideline",
  "@id" : "https://www.pharmgkb.org/data/guideline/PA166104973",
  "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
  "id" : "PA166104973",
  "name" : "Dutch Pharmacogenetics Working Group Guideline for oxycodone and CYP2D6",
  "relatedChemicals" : [ {
    "objCls" : "Chemical",
    "@id" : "https://www.pharmgkb.org/data/chemical/PA450741",
    "@context" : "https://www.pharmgkb.org/jsonld/chemical.jsonld",
    "id" : "PA450741",
    "name" : "oxycodone"
  } ],
  "relatedGenes" : [ {
    "objCls" : "Gene",
    "@id" : "https://www.pharmgkb.org/data/gene/PA128",
    "@context" : "https://www.pharmgkb.org/jsonld/gene.jsonld",
    "id" : "PA128",
    "symbol" : "CYP2D6",
    "name" : "cytochrome P450, family 2, subfamily D, polypeptide 6"
  } ],
  "source" : "DPWG",
  "summaryHtml" : "<p>Use an alternate drug rather than oxycodone (not codeine or tramadol) for CYP2D6 poor and intermediate metabolizer patients, or be alert to insufficient pain relief. For CYP2D6 ultra metabolizer patients, use an alternate drug rather than oxycodone (not codeine or tramadol), or be alert to adverse drug events.  </p>",
  "textHtml" : "<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for oxycodone based on CYP2D6 genotype [Article:<a href=\"/pmid/21412232\">21412232</a>].  They recommend using an alternate drug for poor, intermediate and ultra metabolizer patients.</p><table class=\"table table-striped table-condensed table-hover table-bordered\"><tr><th> Phenotype (Genotype) </th><th> Therapeutic Dose Recommendation </th><th> Level of Evidence </th><th> Clinical Relevance </th></tr><tr><td> PM (2 inactive alleles) </td><td> Insufficient data to allow calculation of dose adjustment.  Select alternate drug - not tramadol or codeine - or be alert to symptoms of insufficient pain relief.  </td><td> Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints. </td><td> Clinical effect (S): short-lived discomfort (&lt; 48 hr) without permanent injury: e.g. reduced decrease in resting heart rate; reduction in exercise tachycardia; decreased pain relief from oxycodone; ADE resulting from increased bioavailability of atomoxetine (decreased appetite, insomnia, sleep disturbance etc); neutropenia &gt; 1.5x10^9/l; leucopenia &gt; 3.0x10^9/l; thrombocytopenia  &gt; 75x10^9/l; moderate diarrhea not affecting daily activities; reduced glucose increase following oral glucose tolerance test. </td></tr><tr><td> IM (2 decreased activity alleles, or 1 active and 1 inactive allele, or 1 decreased activity and 1 inactive allele) </td><td> Insufficient data to allow calculation of dose adjustment.  Select alternate drug - not tramadol or codeine - or be alert to symptoms of insufficient pain relief.    </td><td> Published controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpoints. </td><td> Clinical effect (NS). Kinetic effect (NS). </td></tr><tr><td> UM (gene duplication in absence of inactive or decreased activity alleles) </td><td> Insufficient data to allow calculation of dose adjustment.  Select alternate drug (NOT tramadol or codeine) or be alert to ADEs (e.g., nausea, vomiting, constipation, respiratory depression, confusion, urinary retention).   </td><td> Published incomplete case reports. Product information. </td><td> Minor clinical effect (S): QTc prolongation (&lt;450 ms men, &lt;470 ms women); INR increase &lt; 4.5. Kinetic effect (S). </td></tr></table><table class=\"table table-striped table-condensed table-hover table-bordered\"><tr><th> Allele Type </th><th> Alleles </th></tr><tr><td> active </td><td> *1, *2, *33, *35 </td></tr><tr><td> decreased activity </td><td> *9, *10, *17, *29, *36, *41  </td></tr><tr><td> inactive </td><td> *3-*8, *11-*16, *19-*21, *38, *40, *42 </td></tr></table><ul><li>*See <a href=\"http://www.pharmgkb.org/home/dutch_pharmacogenetics_working_group.jsp\">Methods</a> or <a href=\"http://www.pharmgkb.org/pmid/18253145\">PMID: 18253145</a> for definition of \"moderate\" quality.</li><li>S: statistically significant difference.</li><li>NS: not statistically significant difference.</li></ul>"
}